Update on allergen immunotherapy for asthma.

IF 2.7 3区 医学 Q2 RESPIRATORY SYSTEM
Current Opinion in Pulmonary Medicine Pub Date : 2026-05-01 Epub Date: 2026-02-25 DOI:10.1097/MCP.0000000000001259
R John Looney
{"title":"Update on allergen immunotherapy for asthma.","authors":"R John Looney","doi":"10.1097/MCP.0000000000001259","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>The usefulness of allergen-specific immunotherapy for asthma is controversial. Publications from 2024 and 2025 on allergen immunotherapy for asthma will be reviewed.</p><p><strong>Recent findings: </strong>A trial of house dust mite for asthma was strikingly positive for a subset of patients with variant alleles in chromosome 17q12-21. A trail of cockroach immunotherapy for asthma was negative based on nasal challenge. However, there were promising effects on T cells. New allergen-specific vaccines using allergoids and adjuvants are being developed in Europe and look promising for reducing the number of injections and improving safety. Small clinical trials have shown that trained immunity vaccines containing bacterial lysates can reduce wheezing in young children and animal models suggest these vaccines can affect allergen sensitization and asthma. Recent reviews of multiple clinical trials have shown allergen-specific immunotherapy can reduce symptoms and medications in asthmatic individuals but not objective measures of lung fucntion. Recent reviews of combining biologics with allergen-immunotherapy suggest improved safety.</p><p><strong>Summary: </strong>Allergen-specific immunotherapy remains an important treatment for allergic rhinitis and conjunctivitis and can be used safely in patients with mild or moderate well controlled asthma. Several new approaches look promising but need a lot more work.</p>","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"226-231"},"PeriodicalIF":2.7000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Pulmonary Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MCP.0000000000001259","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of review: The usefulness of allergen-specific immunotherapy for asthma is controversial. Publications from 2024 and 2025 on allergen immunotherapy for asthma will be reviewed.

Recent findings: A trial of house dust mite for asthma was strikingly positive for a subset of patients with variant alleles in chromosome 17q12-21. A trail of cockroach immunotherapy for asthma was negative based on nasal challenge. However, there were promising effects on T cells. New allergen-specific vaccines using allergoids and adjuvants are being developed in Europe and look promising for reducing the number of injections and improving safety. Small clinical trials have shown that trained immunity vaccines containing bacterial lysates can reduce wheezing in young children and animal models suggest these vaccines can affect allergen sensitization and asthma. Recent reviews of multiple clinical trials have shown allergen-specific immunotherapy can reduce symptoms and medications in asthmatic individuals but not objective measures of lung fucntion. Recent reviews of combining biologics with allergen-immunotherapy suggest improved safety.

Summary: Allergen-specific immunotherapy remains an important treatment for allergic rhinitis and conjunctivitis and can be used safely in patients with mild or moderate well controlled asthma. Several new approaches look promising but need a lot more work.

过敏原免疫治疗哮喘的最新进展。
综述目的:过敏原特异性免疫治疗哮喘的有效性是有争议的。将回顾2024年和2025年关于哮喘过敏原免疫治疗的出版物。最近的发现:一项室内尘螨治疗哮喘的试验对染色体17q12-21变异等位基因的患者亚群显著阳性。基于鼻腔刺激的蟑螂免疫治疗哮喘的试验结果为阴性。然而,对T细胞有很好的效果。欧洲正在开发使用类过敏原和佐剂的新型过敏原特异性疫苗,有望减少注射次数并提高安全性。小型临床试验表明,含有细菌裂解物的训练免疫疫苗可以减少幼儿的喘息,动物模型表明这些疫苗可以影响过敏原致敏和哮喘。最近对多项临床试验的回顾表明,过敏原特异性免疫疗法可以减轻哮喘患者的症状和药物治疗,但不能客观地衡量肺功能。最近对生物制剂与过敏原免疫疗法联合的综述表明安全性得到了提高。摘要:过敏原特异性免疫治疗仍然是变应性鼻炎和结膜炎的重要治疗方法,可以安全地用于轻度或中度控制良好的哮喘患者。一些新方法看起来很有希望,但需要做更多的工作。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
109
审稿时长
6-12 weeks
期刊介绍: ​​​​​​Current Opinion in Pulmonary Medicine is a highly regarded journal offering insightful editorials and on-the-mark invited reviews, covering key subjects such as asthma; cystic fibrosis; infectious diseases; diseases of the pleura; and sleep and respiratory neurobiology. Published bimonthly, each issue of Current Opinion in Pulmonary Medicine introduces world renowned guest editors and internationally recognized academics within the pulmonary field, delivering a widespread selection of expert assessments on the latest developments from the most recent literature.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书